Abstract
The proportion of anal cancer cases that produce elevated carcinoembryonic antigen (CEA) levels is not well described in the medical literature. In this study, we used electronic health record data from a single urban cancer center to identify patients from 2004–2018 with anal cancer who have also had a pre-initial treatment CEA measurement. We identified 40 patients who met our eligibility criteria. Of those, 11 (27.5%) had an elevated pretreatment CEA. Elevated CEA was not associated with any of the clinical or demographic covariates; however, three out of five patients with a recurrence had an elevated CEA.
Declaration of interest
Dr. Neugut has served as a consultant to Eisai, Otsuka, Hospira, and United Biosource Corporation. He is on the scientific advisory board of EHE, Intl. Dr. O’Neil has received an honorarium from Ipsen. No other authors have any conflicts of interest or disclosures.